44Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
South Africa
Neuroscience Intelligence
South Africa neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #48 of 50 · Data maturity A · Research score 26.9 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
2Recruiting trials
25Publications
29Institutions
Executive interpretation
South Africa ranks #48 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Pfizer40 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.40 recruiting
Merck Sharp & Dohme LLC42 recruiting
Sumitomo Pharma America, Inc.30 recruiting
Forest Laboratories20 recruiting
Novo Nordisk A/S20 recruiting
Bristol-Myers Squibb10 recruiting
Boehringer Ingelheim10 recruiting
BRC Operations Pty. Ltd.10 recruiting
Daiichi Sankyo10 recruiting
Disease activity
Parkinsons9trials
Alzheimers7trials
Depression5trials
Pain Neuropathy4trials
Autism4trials
Stroke3trials
Other Neurology2trials
Epilepsy2trials
Schizophrenia2trials
Bipolar Disorder2trials
Research institutions
International Centre for Genetic Engineering and BiotechnologyOpenAlexlinked institution
University of the Western CapeOpenAlexlinked institution
University of Fort HareOpenAlexlinked institution
Department of Science,Technology and InnovationOpenAlexlinked institution
University of South AfricaOpenAlexlinked institution
Department of HealthOpenAlexlinked institution
Nelson Mandela UniversityOpenAlexlinked institution
Durban University of TechnologyOpenAlexlinked institution
Johannesburg HospitalOpenAlexlinked institution
Alan J Flisher Centre for Public Mental HealthOpenAlexlinked institution
Clinical evidence trail
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT05064059A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)COMPLETED
NCT04777409A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)COMPLETED
NCT04533529A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With SeltorexantCOMPLETED
NCT04305054Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)COMPLETED
NCT03575052A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCOMPLETED
NCT03574597Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityCOMPLETED
NCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseTERMINATED
NCT03114657A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)TERMINATED
Research evidence trail
PUBMEDSuicidal thoughts and behaviours in Cape Town: A cross-sectional study of prevalence and social, contextual, and clinical correlates.2026-12-01
PUBMEDFive-year outcomes in a randomised controlled trial of prolonged exposure therapy and supportive counselling for post-traumatic stress disorder in adolescents: a task-shifted intervention.2026-12-01
PUBMEDShared and specific associations of amygdala nuclei volumes with PTSD symptom domains and childhood trauma: An ENIGMA-PGC PTSD mega-analysis.2026-11-01
PUBMEDProtocol for a cluster randomized controlled trial among young people and their peers to reduce substance use and inequitable gender beliefs in Southern Africa.2026-10-14
PUBMEDSystematic Review and Meta-analysis of Prevalence of Mental Disorders and Suicidality Among Children and Adolescents Living with HIV in South Africa.2026-10-07
PUBMEDPsychiatric Comorbidities in 7-12 Year Old Children Diagnosed With ADHD in South Africa: A Record Review.2026-10-01
PUBMEDExamining the structure of post-traumatic stress symptoms in South Africa: A latent class approach.2026-10-01
PUBMEDSexual orientation and clinical outcome trajectories over 24 months of treatment in first-episode schizophrenia.2026-10-01
PUBMEDDigital health technologies for supporting home-based rehabilitation and management of children with cerebral palsy: a scoping review.2026-08-19
PUBMEDExploring occupational therapists' perceptions of the use of functional electrical stimulation in adult stroke rehabilitation.2026-06-09
PUBMEDRethinking rituximab in neuroimmunology: Real-world efficacy, cost-effectiveness, and long-term remission.2026-06-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.